We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.
- Authors
Cui, RR; Wright, JD; Hou, JY; Cui, R R; Wright, J D; Hou, J Y
- Abstract
Uterine leiomyosarcoma (LMS) are rare but aggressive tumours with poor clinical outcomes regardless of stage. Most tumours are identified by histopathology at time of surgery, and pre-operative diagnosis remains a clinical challenge. Management of early-stage LMS relies on surgical resection. Cytotoxic chemotherapy remains the mainstay of therapy for advanced-stage, recurrent or metastatic LMS, and includes single or combination doxorubicin-, ifosfamide- or gemcitabine-based regimens. Recent interest in genetic biomarkers led to developments of targeted therapies for LMS, although more research is needed to understand the molecular complexities underlying LMS to guide the development of novel treatment strategies.<bold>Tweetable Abstract: </bold>The diagnosis and treatment of uterine LMS is challenging. Novel biomarkers offer hope for future therapies.
- Subjects
LEIOMYOSARCOMA; UTERINE cancer; MOLECULAR biology; HEALTH outcome assessment; HISTOPATHOLOGY; CANCER chemotherapy; ANTINEOPLASTIC agents; DRUG therapy; DISEASE susceptibility; GENETIC mutation; UTERUS; UTERINE tumors; TUMOR treatment; THERAPEUTICS
- Publication
BJOG: An International Journal of Obstetrics & Gynaecology, 2017, Vol 124, Issue 7, p1028
- ISSN
1470-0328
- Publication type
journal article
- DOI
10.1111/1471-0528.14579